Prosecution Insights
Last updated: August 06, 2026
Application No. 18/255,514

BCMA-TARGETED CHIMERIC ANTIGEN RECEPTORS

Final Rejection §102
Filed
Jun 01, 2023
Priority
Dec 02, 2020 — provisional 63/120,692 +5 more
Examiner
NICKOL, GARY B
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Abelzeta Ltd.
OA Round
2 (Final)
44%
Grant Probability
Moderate
3-4
OA Rounds
7m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
28 granted / 63 resolved
-15.6% vs TC avg
Strong +29% interview lift
Without
With
+29.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
46 currently pending
Career history
103
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
22.4%
-17.6% vs TC avg
§102
21.8%
-18.2% vs TC avg
§112
37.4%
-2.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 63 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The Amendment filed May 4, 2026 in response to the Non-final rejection of February 4, 2026 is acknowledged and has been entered. Claims 1-14, 19-20, 22-23, and 34 were amended or previously presented and are presently under consideration. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action. Rejections Withdrawn The rejection of Claim 34 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph is withdrawn in view of applicant’s amendments. The rejection of Claims 1-20, 22-23, and 34 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is withdrawn in view of applicant’s amendments thereto. All non-statutory double patenting rejections made in the non-final rejection of 02/04/2026 (Paragraphs 29-26) are withdrawn in view of applicant’s filing of terminal disclaimers. Rejections Maintained Claim(s) 1-14, 19-20, and 22-23 remain rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2019/196713 (Wei et al., published 10/17/2019, IDS.) for the reasons of record. Applicants argue that Wei et al. (WO2019/196713) does not constitute prior art because the present application is a 371 national stage of PCT/US21/61410, which claims priority to U.S. Patent Application No. 17/476,661, which is a continuation application of U.S. Patent Application No. 16/881,668, which is a continuation in-part of PCT/CN2019/081064 published as WO2019/196713 (Wei et al.). This argument has been considered but is not found persuasive. According to the latest official filing receipt (05/20/2024) in this application, there is no claim of priority to PCT/CN2019/081064. The earliest date of priority is 12/02/2020 based on provisional application 63/120692: PNG media_image1.png 230 556 media_image1.png Greyscale Further, the application data sheet filed 05/08/2024 does not include PCT/CN2019/081064 in the continuity data. Thus, Applicant’s arguments have been considered but have not been found persuasive. Allowable Subject Matter Claim 34 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GARY B NICKOL, Ph.D. whose telephone number is (571)272-0835. The examiner can normally be reached M-F 9AM-5:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GARY B NICKOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Jun 01, 2023
Application Filed
Feb 04, 2026
Non-Final Rejection mailed — §102
May 04, 2026
Response Filed
Jun 22, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692514
LIVING CELLS ENGINEERED WITH POLYPHENOL-FUNCTIONALIZED BIOLOGICALLY ACTIVE NANOCOMPLEXES
3y 8m to grant Granted Jul 28, 2026
Patent 12679887
ANTI-INTERLEUKIN-17A ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
5y 8m to grant Granted Jul 14, 2026
Patent 12678461
CD28H DOMAIN-CONTAINING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
3y 9m to grant Granted Jul 14, 2026
Patent 12678494
Immunogenic Composition Comprising Multivalent Streptococcus Pneumoniae Polysaccharide-Protein Conjugates
3y 0m to grant Granted Jul 14, 2026
Patent 12674803
DIAGNOSIS OF BABESIA USING BABESIA RECOMBINANT PROTEINS
4y 2m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
44%
Grant Probability
74%
With Interview (+29.3%)
3y 9m (~7m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month